Literature DB >> 31638431

p38γ MAPK contributes to left ventricular remodeling after pathologic stress and disinhibits calpain through phosphorylation of calpastatin.

Aminah A Loonat1, E Denise Martin1, Negin Sarafraz-Shekary1, Katharina Tilgner1, Nicholas T Hertz2, Rebecca Levin2, Kevan M Shokat2, Alma L Burlingame2, Pelin Arabacilar1, Shahzan Uddin1, Max Thomas1, Michael S Marber1, James E Clark1.   

Abstract

Despite the high and preferential expression of p38γ MAPK in the myocardium, little is known about its function in the heart. The aim of the current study was to elucidate the physiologic and biochemical roles of p38γ in the heart. Expression and subcellular localization of p38 isoforms was determined in mouse hearts. Comparisons of the cardiac function and structure of wild-type and p38γ knockout (KO) mice at baseline and after abdominal aortic banding demonstrated that KO mice developed less ventricular hypertrophy and that contractile function is better preserved. To identify potential substrates of p38γ, we generated an analog-sensitive mutant to affinity tag endogenous myocardial proteins. Among other proteins, this technique identified calpastatin as a direct p38γ substrate. Moreover, phosphorylation of calpastatin by p38γ impaired its ability to inhibit the protease, calpain. We have identified p38γ as an important determinant of the progression of pathologic cardiac hypertrophy after aortic banding in mice. In addition, we have identified calpastatin, among other substrates, as a novel direct target of p38γ that may contribute to the protection observed in p38γKO mice.-Loonat, A. A., Martin, E. D., Sarafraz-Shekary, N., Tilgner, K., Hertz, N. T., Levin, R., Shokat, K. M., Burlingame, A. L., Arabacilar, P., Uddin, S., Thomas, M., Marber, M. S., Clark, J. E. p38γ MAPK contributes to left ventricular remodeling after pathologic stress and disinhibits calpain through phosphorylation of calpastatin.

Entities:  

Keywords:  failure; heart; hypertrophy; kinase; protection

Mesh:

Substances:

Year:  2019        PMID: 31638431      PMCID: PMC6894093          DOI: 10.1096/fj.201701545R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.834


  33 in total

1.  Modulation of rat brain calpastatin efficiency by post-translational modifications.

Authors:  F Salamino; M Averna; I Tedesco; R De Tullio; E Melloni; S Pontremoli
Journal:  FEBS Lett       Date:  1997-08-04       Impact factor: 4.124

Review 2.  New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease.

Authors:  Eva Denise Martin; Gian Felice De Nicola; Michael S Marber
Journal:  Circulation       Date:  2012-07-17       Impact factor: 29.690

3.  Stress-activated protein kinase-3 interacts with the PDZ domain of alpha1-syntrophin. A mechanism for specific substrate recognition.

Authors:  M Hasegawa; A Cuenda; M G Spillantini; G M Thomas; V Buée-Scherrer; P Cohen; M Goedert
Journal:  J Biol Chem       Date:  1999-04-30       Impact factor: 5.157

4.  Cardiac expression and subcellular localization of the p38 mitogen-activated protein kinase member, stress-activated protein kinase-3 (SAPK3).

Authors:  Naomi W Court; Cristobal G dos Remedios; Jacky Cordell; Marie A Bogoyevitch
Journal:  J Mol Cell Cardiol       Date:  2002-04       Impact factor: 5.000

5.  p38-{gamma}-dependent gene silencing restricts entry into the myogenic differentiation program.

Authors:  Mark A Gillespie; Fabien Le Grand; Anthony Scimè; Shihuan Kuang; Julia von Maltzahn; Vanessa Seale; Ana Cuenda; Jeffrey A Ranish; Michael A Rudnicki
Journal:  J Cell Biol       Date:  2009-12-21       Impact factor: 10.539

6.  Targeted proteolysis sustains calcineurin activation.

Authors:  Natalie Burkard; Jan Becher; Cornelia Heindl; Ludwig Neyses; Kai Schuh; Oliver Ritter
Journal:  Circulation       Date:  2005-02-21       Impact factor: 29.690

7.  Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes.

Authors:  Ying Li; Jian Ma; Huaqing Zhu; Manpreet Singh; David Hill; Peter A Greer; J Malcolm Arnold; E Dale Abel; Tianqing Peng
Journal:  Diabetes       Date:  2011-09-12       Impact factor: 9.461

8.  Over-expression of calpastatin inhibits calpain activation and attenuates post-infarction myocardial remodeling.

Authors:  Tingqiao Ye; Qiang Wang; Yan Zhang; Xiaofeng Song; Dachun Yang; De Li; Dan Li; Linan Su; Yongjian Yang; Shuangtao Ma
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

9.  Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction.

Authors:  Matteo Vatta; Bhagyalaxmi Mohapatra; Shinawe Jimenez; Ximena Sanchez; Georgine Faulkner; Zeev Perles; Gianfranco Sinagra; Jiuann-Huey Lin; Thuy M Vu; Qiang Zhou; Karla R Bowles; Andrea Di Lenarda; Lisa Schimmenti; Michelle Fox; Michelle A Chrisco; Ross T Murphy; William McKenna; Perry Elliott; Neil E Bowles; Ju Chen; Giorgio Valle; Jeffrey A Towbin
Journal:  J Am Coll Cardiol       Date:  2003-12-03       Impact factor: 24.094

10.  Mechanism and consequence of the autoactivation of p38α mitogen-activated protein kinase promoted by TAB1.

Authors:  Eva Denise Martin; Apirat Chaikuad; Rekha Bassi; Gian Felice DeNicola; James Clark; Luigi Martino; Sharwari Verma; Pierre Sicard; Renée Tata; R Andrew Atkinson; Stefan Knapp; Maria R Conte; Michael S Marber
Journal:  Nat Struct Mol Biol       Date:  2013-09-15       Impact factor: 15.369

View more
  2 in total

Review 1.  Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy.

Authors:  David Aluja; Sara Delgado-Tomás; Marisol Ruiz-Meana; José A Barrabés; Javier Inserte
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

2.  Deletion of p38γ attenuates ethanol consumption- and acetaminophen-induced liver injury in mice through promoting Dlg1.

Authors:  Shuang Hu; Yan Yao; Ze-Yuan Wei; Shu-Xian Wang; Yin-Cui Wu; Ying Hu; Chen-Chen Yang; Jing-Li Min; Liang-Yun Li; Hong Zhou; Jun-Fa Yang; Jun Li; Tao Xu
Journal:  Acta Pharmacol Sin       Date:  2021-11-17       Impact factor: 7.169

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.